Quick Answer
ENDO 2026 data shows GLP-1 drugs improve testosterone and sperm quality in obese Indian men, and unlike TRT, they do not harm sperm production — making them a better first-line option.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
For Indian men struggling with obesity, low testosterone, or fertility concerns, new clinical data presented at ENDO 2026 brings genuinely encouraging news. A review of five randomised controlled trials found that GLP-1 medications like semaglutide (Ozempic) and liraglutide do not harm male hormones or fertility — and in obese men with low testosterone, they may actually improve sperm quality and testosterone levels more effectively than testosterone replacement therapy alone.
What Was Presented at ENDO 2026
The research was presented at the Endocrine Society's annual meeting in Chicago in June 2026. Researchers reviewed data from five randomised controlled trials examining the effects of GLP-1 medications on male reproductive health.
In a 24-week semaglutide trial involving men with obesity and type 2 diabetes, participants showed significant improvements in sperm morphology — the shape of sperm cells, which is a key determinant of fertility — alongside improvements in cholesterol levels. Importantly, testosterone levels and other reproductive hormones remained stable throughout treatment, directly addressing the concern that a powerful metabolic drug might disrupt the hormonal system.
A separate 16-week study using liraglutide focused on obese men who had low testosterone caused by excess body fat. These men saw meaningful increases in testosterone and related hormones, with overall health improvements that exceeded what was seen with testosterone replacement therapy alone. The researchers noted that GLP-1 medications preserve and may restore fertility, while TRT is well-established to harm sperm production in a significant proportion of men.
Why This Matters for Indian Men Specifically
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
India has a quiet but serious male fertility challenge. Studies estimate that roughly 50 percent of infertility cases in Indian couples involve a male factor, yet male fertility remains significantly under-discussed and under-treated. At the same time, India has one of the largest populations of men with obesity and type 2 diabetes in the world — two conditions directly linked to low testosterone and poor sperm quality through a condition called hypogonadism.
Excess body fat, particularly visceral fat around the abdomen, converts testosterone into oestrogen through a process called aromatisation. The more visceral fat a man carries, the lower his effective testosterone levels become. This leads to reduced sex drive, fatigue, reduced muscle mass, difficulty maintaining erections, and importantly, impaired sperm production. Indian men tend to accumulate visceral fat at lower body weights than Western populations, meaning this process can start earlier and progress faster.
Many Indian men with these symptoms are currently being prescribed testosterone replacement therapy. While TRT restores testosterone levels, it paradoxically suppresses the body's own signal to produce sperm, leading to severely reduced or absent sperm in the ejaculate — a serious problem for men who still want to father children. This suppression can persist even after stopping TRT.
The ENDO 2026 data suggests GLP-1 medications take a fundamentally different approach. By driving meaningful weight loss and reducing visceral fat, they address the root hormonal cause. As visceral fat decreases, testosterone recovers naturally — without suppressing sperm production. This makes GLP-1 therapy a potentially far more appropriate first choice than TRT for obese men who want to preserve or improve their fertility while also improving their hormonal and metabolic health.
What Indian Men Should Consider
If you are an Indian man with obesity or type 2 diabetes and are also experiencing symptoms of low testosterone — fatigue, reduced libido, difficulty with erections, or concerns about fertility — the ENDO 2026 findings suggest the conversation with your doctor should begin with GLP-1 therapy rather than TRT.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
GLP-1 medications are not a guaranteed treatment for male infertility. The trials reviewed were relatively small and the findings are promising but preliminary. A specialist should evaluate you properly — measuring testosterone, LH, FSH, and semen parameters — before any treatment is decided. For men already on TRT who want to transition, stopping suddenly is not recommended and a gradual supervised plan is essential.
Access to GLP-1 therapy in India has improved greatly since the semaglutide patent expired in March 2026. Generic semaglutide from approved Indian manufacturers including Sun Pharma and Cipla is now available at approximately Rs 3,500 to Rs 6,000 per month, making it a realistic option for a much larger number of Indian men than before.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Endocrine Society (ENDO 2026) — https://www.endocrine.org/news-and-advocacy/news-room/2026/natesh-press-release-endo-2026 2. Medscape — https://www.medscape.com/viewarticle/male-fertility-not-harmed-glp-1s-and-maybe-helped-2026a1000k9m 3. TechTimes — https://www.techtimes.com/articles/318423/20260615/glp-1-drugs-may-boost-male-fertility-obese-men-new-data-challenge-trt-first-approach.htm
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.